Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

111.94 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,554,742
Open 112.88
Bid (Size) 111.11 (1)
Ask (Size) 111.90 (1)
Prev. Close 111.95
Today's Range 111.79 - 113.02
52wk Range 94.73 - 148.15
Shares Outstanding N/A
Dividend Yield 1.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Novo Nordisk's ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. 
Via Benzinga

Performance

YTD
+9.63%
+9.63%
1 Month
-2.73%
-2.73%
3 Month
-11.16%
-11.16%
6 Month
-10.15%
-10.15%
1 Year
+14.03%
+14.03%

More News

Read More
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Via MarketBeat
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Via Benzinga
Exposures Product Safety
How Is The Market Feeling About Novo Nordisk?
Via Benzinga
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
Smitten With Novo Nordisk
Via Talk Markets
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
Via Investor's Business Daily
AMD Earnings Show Power Of Nvidia Software, ADP Data Defies Expectations
Via Benzinga
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Via The Motley Fool
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
Via The Motley Fool
Neuralink's Promise For Alzheimer's Has A Crucial Time Window — Elon Musk Explains Why
Via Benzinga
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Via The Motley Fool
Benzinga Bulls And Bears: Nvidia, Tesla, MicroStrategy, Plug Power — And Crypto Traders Anticipate Dogecoin Topping 50 Cents
Via Benzinga
Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows
Via Benzinga
Exposures Product Safety
Hims & Hers Stock Dropped: Here's What You Need to Know
Via The Motley Fool
Monster and Celsius Energized: Which Stock Offers More Upside?
Via MarketBeat
Topics ETFs
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Exposures Product Safety
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Via Benzinga
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via Chartmill
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Via Investor's Business Daily
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.